Results 51 to 60 of about 47,434 (363)

Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology

eLife, 2021
We developed genetic-epigenetic tissue mapping (GETMap) to determine the tissue composition of plasma DNA carrying genetic variants not present in the constitutional genome through comparing their methylation profiles with relevant tissues.
Wanxia Gai, Ze Zhou, Sean Agbor-Enoh, Xiaodan Fan, Sheng Lian, Peiyong Jiang, Suk Hang Cheng, John Wong, Stephen L Chan, Moon Kyoo Jang, Yanqin Yang, Raymond HS Liang, Wai Kong Chan, Edmond SK Ma, Tak Y Leung, Rossa WK Chiu, Hannah Valantine, KC Allen Chan, YM Dennis Lo   +18 more
doaj   +1 more source

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. [PDF]

, 2020
PurposeStudies have demonstrated an association between quantity of circulating tumor DNA (ctDNA) and poorer survival. We investigated the relationship between percent ctDNA (%ctDNA), total number of ctDNA alterations, and overall survival (OS) in liquid
Goodman, Aaron, Khagi, Yulian, Kurzrock, Razelle, Riviere, Paul, Vu, Peter   +4 more
core  

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study [PDF]

, 2018
open32Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection.openKhan, Khurum; Rata,

core   +1 more source

A clinician’s handbook for using ctDNA throughout the patient journey

Molecular Cancer, 2022
Background The promise of precision cancer medicine presently centers around the genomic sequence of a patient’s tumor being translated into timely, actionable information to inform clinical care.
Samantha O. Hasenleithner, M. Speicher
semanticscholar   +1 more source

The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children : a review [PDF]

, 2020
Cell-free DNA profiling using patient blood is emerging as a non-invasive complementary technique for cancer genomic characterization. Since these liquid biopsies will soon be integrated into clinical trial protocols for pediatric cancer treatment ...
Astrahantseff, Kathy, Chaali-Vlug, Roos, De Preter, Katleen, De Wilde, Bram, Deubzer, Hedwig, Lammens, Tim, Laureys, Genevieve, Schleiermacher, Gudrun, Speleman, Franki, Tytgat, Godelieve AM, Van Paemel, Ruben, Van Roy, Nadine, Willems, Leen   +12 more
core   +2 more sources

Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).

Clinical Cancer Research, 2021
PURPOSE We assessed whether perioperative circulating tumor DNA (ctDNA) could be a biomarker for early detection of molecular residual disease (MRD) and prediction of postoperative relapse in resected non-small cell lung cancer (NSCLC).
L. Xia, J. Mei, Ran Kang, Senyi Deng, Yaohui Chen, Ying Yang, G. Feng, Yulan Deng, Fanyi Gan, Yidan Lin, Q. Pu, Lin Ma, F. Lin, Yong Yuan, Yang Hu, Chenglin Guo, H. Liao, Chengwu Liu, Yunke Zhu, Wenping Wang, Zheng Liu, Yuyang Xu, Kaidi Li, Chuan Li, Qingyun Li, Ji He, Weizhi Chen, Xiao-long Zhang, Ying-li Kou, Yun Wang, Zhu Wu, Guowei Che, Longqi Chen, Lunxu Liu   +33 more
semanticscholar   +1 more source

Circulating Tumor Cells and ctDNA in Sarcomas

, 2022
Sarcomas are clustered in two oncological entities named bone and soft-tissue sarcomas. Both are rare cancers originating from the mesenchyme, characterized by their propensity to induce the development of lung metastases. Sarcoma cells escaping from the primary tumor site, spread to the pulmonary tissue through the bloodstream where they found a ...
Heymann, Dominique, Jubelin, Camille, Cochonneau, Denis, Moranton, Emilie, Muñoz-Garcia, Javier   +4 more
openaire   +2 more sources

ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

BMC Cancer, 2023
Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC).
S. Slater, A. Bryant, Hsiang-Chi Chen, R. Begum, I. Rana, M. Aresu, C. Peckitt, O. Zhitkov, R. Lazaro-Alcausi, V. Borja, Rachel Powell, David Lowery, M. Hubank, T. Rich, G. Anandappa, I. Chau, N. Starling, D. Cunningham   +17 more
semanticscholar   +1 more source

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors

PLOS Medicine, 2021
Christopher Abbosh and Charles Swanton discuss circulating tumor DNA as a potential biomarker for neoadjuvant treatment response in solid tumors.
Charles Swanton, Charles Swanton, Christopher Abbosh   +2 more
openaire   +6 more sources

ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy

Frontiers in Oncology, 2023
Background Sensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally advanced non-small ...
E. Lebow, N. Shaverdian, J. Eichholz, L. Kratochvil, Megan McCune, Y. Murciano-Goroff, J. Jee, J. Eng, J. Chaft, M. Kris, E. Kalashnikova, Jordan Feeney, C. Scalise, Sumedha Sudhaman, C. Palsuledesai, M. Malhotra, Michael Krainock, H. Sethi, A. Aleshin, Minetta C. Liu, A. Shepherd, A. Wu, Charles B. Simone, D. Gelblum, Kaylie Johnson, C. Rudin, D. Gomez, P. Razavi, J. Reis-Filho, J. Isbell, Bob T. Li, A. Rimner   +31 more
semanticscholar   +1 more source